UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Modeling The Economic Burden Of Adult Vaccine-Preventable Diseases In The United States

Health Affairs, 2016-11, Vol.35 (11), p.2124-2132

2016

Volltextzugriff (PDF)

Evaluation of Healthcare Use and Clinical Outcomes of Alvimopan in Patients Undergoing Bowel Resection: A Propensity Score-Matched Analysis

Diseases of the colon & rectum, 2018-12, Vol.61 (12), p.1418-1425

2018

Volltextzugriff (PDF)

A clinical practice comparison of patients with chronic lymphocytic leukemia with and without deletion 17p receiving first-line treatment with ibrutinib

Haematologica (Roma), 2022-11, Vol.107 (11), p.2630-2640

2022

Volltextzugriff (PDF)

Impact of high- versus low-dose neuromuscular blocking agent administration on unplanned 30-day readmission rates in retroperitoneal laparoscopic surgery

PloS one, 2018-05, Vol.13 (5), p.e0197036-e0197036

2018

Volltextzugriff (PDF)

Investigation of intraoperative dosing patterns of neuromuscular blocking agents

Journal of clinical monitoring and computing, 2019-06, Vol.33 (3), p.455-462

2019

Volltextzugriff (PDF)

P1110: REAL‐WORLD TREATMENT PATTERNS OF BRUTON TYROSINE KINASE INHIBITORS (BTKI) IN PATIENTS WITH MANTLE CELL LYMPHOMA (MCL) IN COMMUNITY ONCOLOGY PRACTICES IN THE UNITED STATES (US)

HemaSphere, 2023-08, Vol.7 (S3), p.e22348b6-n/a

2023

Volltextzugriff (PDF)

P1093: MATCHING‐ADJUSTED INDIRECT COMPARISON (MAIC) OF ZANUBRUTINIB (ZANU) VERSUS IBRUTINIB (IBRU) IN RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA (R/R MZL)

HemaSphere, 2023-08, Vol.7 (S3), p.e8409315-n/a

2023

Volltextzugriff (PDF)

P1113: COMPARATIVE EFFICACY OF ZANUBRUTINIB (ZANU) VERSUS RITUXIMAB (RTX) IN RELAPSED MARGINAL ZONE LYMPHOMA (MZL): MATCHING-ADJUSTED INDIRECT COMPARISON (MAIC)

HemaSphere, 2023-08, Vol.7 (S3), p.e10013c4

2023

Volltextzugriff (PDF)

Similar efficacy of ibrutinib arms across ALPINE and ELEVATE-RR trials in relapsed/refractory chronic lymphocytic leukemia: a matching-adjusted indirect comparison

Blood cancer journal (New York), 2024-05, Vol.14 (1), p.77-77, Article 77

2024

Volltextzugriff (PDF)

P640: ZANUBRUTINIB VS IBRUTINIB IN RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA AND SMALL LYMPHOCYTIC LYMPHOMA (R/R CLL/SLL): IMPACT ON HEALTH‐RELATED QUALITY OF LIFE (HRQOL)

HemaSphere, 2023-08, Vol.7 (S3), p.e02428b9-n/a

2023

Volltextzugriff (PDF)

A real‐world study to assess the association of cardiovascular adverse events (CVAEs) with ibrutinib as first‐line (1L) treatment for patients with chronic lymphocytic leukaemia (CLL) in the United States

EJHaem, 2023-02, Vol.4 (1), p.135-144

2023

Volltextzugriff (PDF)

Health disparities: A barrier to high-quality care

American journal of health-system pharmacy, 2005-09, Vol.62 (18), p.1873-1882

2005

Volltextzugriff (PDF)

Real-world evidence of impact of atrial fibrillation (AF) on clinical and economic outcomes in patients with chronic lymphocytic leukemia (CLL)

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.e18729-e18729

2022

Volltextzugriff (PDF)

Real-world treatment (tx) patterns and economic burden of patients (pts) with marginal zone lymphoma (MZL)

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.e18730-e18730

2022

Volltextzugriff (PDF)

Real-World Treatment Patterns, Adherence and Healthcare Resource Utilization for Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia Among Veterans in the United States

Blood, 2021-11, Vol.138 (Supplement 1), p.4079-4079

2021

Volltextzugriff (PDF)

P1113: COMPARATIVE EFFICACY OF ZANUBRUTINIB (ZANU) VERSUS RITUXIMAB (RTX) IN RELAPSED MARGINAL ZONE LYMPHOMA (MZL): MATCHING‐ADJUSTED INDIRECT COMPARISON (MAIC)

HemaSphere, 2023-08, Vol.7, p.n/a

2023

Volltextzugriff (PDF)

Real-world treatment switching and sequencing to next line of therapy of zanubrutinib, acalabrutinib, and ibrutinib in CLL/SLL

Journal of clinical oncology, 2024-06, Vol.42 (16_suppl), p.e19022-e19022

2024

Volltextzugriff (PDF)

Real-world adherence and healthcare resource utilization of Bruton tyrosine kinase inhibitors (BTKi) in mantle cell lymphoma

Journal of clinical oncology, 2024-06, Vol.42 (16_suppl), p.e19048-e19048

2024

Volltextzugriff (PDF)

Real-world evaluation of treatment pattern, time to next treatment (TTNT), healthcare resource utilization (HCRU), and cost of care in follicular lymphoma (FL)

Journal of clinical oncology, 2024-06, Vol.42 (16_suppl), p.e19044-e19044

2024

Volltextzugriff (PDF)

OP112 Evaluation Of A Self-Administered Smart Phone-Based Application As A Wellness Measure In A Clinical Trial Of Zanubrutinib

International journal of technology assessment in health care, 2023-12, Vol.39 (S1), p.S31-S31

2023

Volltextzugriff (PDF)

Zanubrutinib vs FCR in Fit Treatment-Naive Patients with Chronic Lymphocytic Leukemia: A Matching-Adjusted Indirect Comparison

Blood, 2023-11, Vol.142 (Supplement 1), p.6522-6522

2023

Volltextzugriff (PDF)

Impact of Real-World Treatment Sequencing Patterns on Time to Next Treatment among Patients with Chronic Lymphocytic Leukemia in the United States

Blood, 2023-11, Vol.142 (Supplement 1), p.5143-5143

2023

Volltextzugriff (PDF)

Toxicity, Progression-Free Survival, and Quality of Life of Patients Treated with Zanubrutinib Versus Ibrutinib: A Q-TWiST Analysis from the ALPINE Study in Relapsed or Refractory Chronic Lymphocytic Leukemia

Blood, 2023-11, Vol.142 (Supplement 1), p.1909-1909

2023

Volltextzugriff (PDF)

Real-World Switching Pattern, Persistence, and Associated Healthcare Resource Utilization of Bruton Tyrosine Kinase Inhibitors for the Treatment of Mantle Cell Lymphoma in the United States

Blood, 2023-11, Vol.142 (Supplement 1), p.5155-5155

2023

Volltextzugriff (PDF)

1 – 25 von 163

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(158)
Mit Volltextzugriff
(124)

Publikationsform

Sprache

Englisch
(163)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(12)

Menü

Weitere Dienste

Einstellungen

Modeling The Economic Burden Of Adult Vaccine-Preventable Diseases In The United States

Evaluation of Healthcare Use and Clinical Outcomes of Alvimopan in Patients Undergoing Bowel Resection: A Propensity Score-Matched Analysis

A clinical practice comparison of patients with chronic lymphocytic leukemia with and without deletion 17p receiving first-line treatment with ibrutinib

Impact of high- versus low-dose neuromuscular blocking agent administration on unplanned 30-day readmission rates in retroperitoneal laparoscopic surgery

Investigation of intraoperative dosing patterns of neuromuscular blocking agents

P1110: REAL‐WORLD TREATMENT PATTERNS OF BRUTON TYROSINE KINASE INHIBITORS (BTKI) IN PATIENTS WITH MANTLE CELL LYMPHOMA (MCL) IN COMMUNITY ONCOLOGY PRACTICES IN THE UNITED STATES (US)

P1093: MATCHING‐ADJUSTED INDIRECT COMPARISON (MAIC) OF ZANUBRUTINIB (ZANU) VERSUS IBRUTINIB (IBRU) IN RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA (R/R MZL)

P1113: COMPARATIVE EFFICACY OF ZANUBRUTINIB (ZANU) VERSUS RITUXIMAB (RTX) IN RELAPSED MARGINAL ZONE LYMPHOMA (MZL): MATCHING-ADJUSTED INDIRECT COMPARISON (MAIC)

Similar efficacy of ibrutinib arms across ALPINE and ELEVATE-RR trials in relapsed/refractory chronic lymphocytic leukemia: a matching-adjusted indirect comparison

P640: ZANUBRUTINIB VS IBRUTINIB IN RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA AND SMALL LYMPHOCYTIC LYMPHOMA (R/R CLL/SLL): IMPACT ON HEALTH‐RELATED QUALITY OF LIFE (HRQOL)

A real‐world study to assess the association of cardiovascular adverse events (CVAEs) with ibrutinib as first‐line (1L) treatment for patients with chronic lymphocytic leukaemia (CLL) in the United States

P1679: HEALTH‐RELATED QUALITY OF LIFE IN PATIENTS (PTS) WITH WALDENSTRÖM MACROGLOBULINEMIA (WM) TREATED WITH ZANUBRUTINIB (ZANU) VS IBRUTINIB (IBR): RESULTS FROM THE PHASE 3 ASPEN TRIAL LONG‐TERM FOLLOW‐UP

Health disparities: A barrier to high-quality care

Real-world evidence of impact of atrial fibrillation (AF) on clinical and economic outcomes in patients with chronic lymphocytic leukemia (CLL)

Real-world treatment (tx) patterns and economic burden of patients (pts) with marginal zone lymphoma (MZL)

Real-World Treatment Patterns, Adherence and Healthcare Resource Utilization for Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia Among Veterans in the United States

P1113: COMPARATIVE EFFICACY OF ZANUBRUTINIB (ZANU) VERSUS RITUXIMAB (RTX) IN RELAPSED MARGINAL ZONE LYMPHOMA (MZL): MATCHING‐ADJUSTED INDIRECT COMPARISON (MAIC)

Real-world treatment switching and sequencing to next line of therapy of zanubrutinib, acalabrutinib, and ibrutinib in CLL/SLL

Real-world adherence and healthcare resource utilization of Bruton tyrosine kinase inhibitors (BTKi) in mantle cell lymphoma

Real-world evaluation of treatment pattern, time to next treatment (TTNT), healthcare resource utilization (HCRU), and cost of care in follicular lymphoma (FL)

OP112 Evaluation Of A Self-Administered Smart Phone-Based Application As A Wellness Measure In A Clinical Trial Of Zanubrutinib

Zanubrutinib vs FCR in Fit Treatment-Naive Patients with Chronic Lymphocytic Leukemia: A Matching-Adjusted Indirect Comparison

Impact of Real-World Treatment Sequencing Patterns on Time to Next Treatment among Patients with Chronic Lymphocytic Leukemia in the United States

Toxicity, Progression-Free Survival, and Quality of Life of Patients Treated with Zanubrutinib Versus Ibrutinib: A Q-TWiST Analysis from the ALPINE Study in Relapsed or Refractory Chronic Lymphocytic Leukemia

Real-World Switching Pattern, Persistence, and Associated Healthcare Resource Utilization of Bruton Tyrosine Kinase Inhibitors for the Treatment of Mantle Cell Lymphoma in the United States

Suchergebnisse filtern